Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine plus flumazenil for improving consciousness in benzodiazepine poisoning
IRCT20091116002717N2Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of caffeine and flumazenil in benzodiazepine overdose (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Level of consciousness and Duration of hospitalization. Started Mar 2024; status: completed.
02
Drugs
caffeineflumazenil
03
Conditions
benzodiazepine overdose
Beyond the preview
Go deeper on IRCT20091116002717N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20091116002717N2.